



Public Health Division
122 West 25th Street, 3rd Floor West
Cheyenne, WY 82002
(307) 777-6004 • 800-599-9754
Fax (307) 777-8687 • www.health.wyo.gov



Michael A. Ceballos
Director

Mark Gordon
Governor

State Health Advisory Supplement

Coronavirus Disease 2019 Supplemental Advisory #12.1

Wyoming Department of Health

September 2, 2020

SUMMARY

This Health Advisory Supplement provides updated information on SARS-CoV-2 testing at the Wyoming Public Health Laboratory (WPHL) and expanded indications for Remdesivir use.

CHANGE TO SARS-CoV-2 TESTING AT THE WPHL

On August 24, the Wyoming Public Health Laboratory (WPHL) changed SARS-CoV-2 testing methods. The new method, which is known as the CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay, allowed for the simultaneous detection of influenza A, influenza B, and SARS-CoV-2. This was a development we were pleased to offer and was based on a test offered to us by CDC.

Unfortunately, we have been informed of unexpected, sudden supply shortages at the federal level related to this test.

As a result, on Tuesday, September 8, WPHL will return to using the 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel. This is the same test performed at WPHL prior to August 24 for detecting COVID-19. Testing results will only include a result for SARS-CoV-2; influenza results will not be included. The ordering process for SARS-CoV-2 testing will not change.

Because we believe the ability to detect both COVID-19 and influenza is valuable, if and when reagents from CDC become consistently available, the WPHL will re-evaluate the ability to once again offer the Flu SC2 multiplex assay. Again, the issue we face is related to supplies rather than any known concerns with test performance.

At this time, WPHL is unable to offer diagnostic testing for influenza. If your facility is an ILINet provider, you will be contacted directly with instructions for submission of samples for influenza surveillance.

EXPANDED INDICATIONS FOR REMDESIVIR USE

The U.S. Food and Drug Administration (FDA) has amended the Emergency Use Authorization (EUA) for Remdesivir. **The FDA now authorizes the use of Remdesivir to treat suspected or laboratory-confirmed COVID-19 in hospitalized adult and pediatric patients. There are no longer requirements for patients to meet certain severity criteria other than hospitalization.**

The amended EUA can be found here: [Amended Remdesivir EUA](#). The fact sheet for healthcare providers can be found here: [Veklury \(remdesivir\) Emergency Use Authorization Fact Sheet for Health Care Providers](#)

WDH continues to receive shipments of Remdesivir. WDH has distributed supplies to hospitals around the state that indicated they would use the medication. Providers at hospitals that have received a stock of Remdesivir do not have to request permission from WDH to use the medication. **However, WDH asks that providers or hospitals with stock notify WDH about medication use to allow us to track the available Remdesivir in Wyoming and patient outcomes.** Please notify WDH by faxing the patient's name, date of birth, date of admission, and expected dosing to our secure fax line at 307-777-7753.

Hospital pharmacies that would like to request doses of Remdesivir to restock their supply should call 1-888-996-9104.

Providers at facilities without Remdesivir stock can request a course of the medication by calling WDH's 24/7 Public Health Emergency Line at 1-888-996-9104. The WDH will make every effort to deliver the requested course within 12 hours of the request.

Providers treating COVID-19 patients with Remdesivir must report all medication errors and all serious adverse events to the FDA. For patients that receive Remdesivir, providers must document in the medical record that the patient or caregiver has been given the [Fact Sheet for Patients And Parents/Caregivers Emergency Use Authorization \(EUA\) Of Veklury® \(remdesivir\) For Coronavirus Disease](#) informed of alternatives to receiving Remdesivir, and informed that Remdesivir is an unapproved drug that is authorized for use under an EUA.

CONTACT INFORMATION

Wyoming healthcare providers and facilities are reminded to check COVID-19 resources available from [WDH](#) and [CDC](#). Healthcare providers or facilities can contact WDH through the following channels:

- Please email questions about preparedness, PPE, infection control, or other non-urgent topics to wdh.covid19@wyo.gov.
- Please contact WPHL with questions about specimen collection, storage, or shipping at 307-777-7431 or WPHL@wyo.gov.
- For WPHL result inquiries, please allow 24 hours upon receipt of the sample to request the status of results. Please email WDH-COVID-RESULTS@wyo.gov with the name of the patient, medical records number, and date of birth.
- **Please use the WDH Public Health Emergency Line (1-888-996-9104) for urgent questions about a specific patient, healthcare personnel exposure, Remdesivir**

request, or other urgent matter. This line is intended ONLY for healthcare providers. Do not share this number with the public.

Please refer questions from the general public to 211 or to the WDH email box (wdh.covid19@wyo.gov).